These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 37843781)
1. ANXA3, associated with YAP1 regulation, participates in the proliferation and chemoresistance of cervical cancer cells. Huang J; Wei W; Kang F; Tan S; Li Y; Lu X; Wang N Genes Genomics; 2023 Dec; 45(12):1575-1586. PubMed ID: 37843781 [TBL] [Abstract][Full Text] [Related]
2. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer. Du R; Liu B; Zhou L; Wang D; He X; Xu X; Zhang L; Niu C; Liu S Cell Death Dis; 2018 Jan; 9(2):126. PubMed ID: 29374148 [TBL] [Abstract][Full Text] [Related]
3. Tumor-Suppressing Effect of Silencing of Annexin A3 Expression in Breast Cancer. Kim JY; Jung EJ; Park HJ; Lee JH; Song EJ; Kwag SJ; Park JH; Park T; Jeong SH; Jeong CY; Ju YT; Lee YJ; Hong SC Clin Breast Cancer; 2018 Aug; 18(4):e713-e719. PubMed ID: 29217453 [TBL] [Abstract][Full Text] [Related]
4. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Pan QZ; Pan K; Weng DS; Zhao JJ; Zhang XF; Wang DD; Lv L; Jiang SS; Zheng HX; Xia JC Mol Carcinog; 2015 Aug; 54(8):598-607. PubMed ID: 24375474 [TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells. Wang L; Li X; Ren Y; Geng H; Zhang Q; Cao L; Meng Z; Wu X; Xu M; Xu K Cancer Sci; 2019 May; 110(5):1609-1620. PubMed ID: 30868675 [TBL] [Abstract][Full Text] [Related]
6. Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells. Zhou T; Li Y; Yang L; Liu L; Ju Y; Li C Oncol Rep; 2017 Jan; 37(1):388-398. PubMed ID: 27878264 [TBL] [Abstract][Full Text] [Related]
7. 33-kDa ANXA3 isoform contributes to hepatocarcinogenesis Guo C; Li N; Dong C; Wang L; Li Z; Liu Q; Ma Q; Greenaway FT; Tian Y; Hao L; Liu S; Sun MZ J Adv Res; 2021 May; 30():85-102. PubMed ID: 34026289 [TBL] [Abstract][Full Text] [Related]
8. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway. Xu R; Yin J; Zhang Y; Zhang S J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268 [TBL] [Abstract][Full Text] [Related]
9. Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS. Zeng X; Wang S; Gui P; Wu H; Li Z Mol Med Rep; 2019 Sep; 20(3):2583-2590. PubMed ID: 31524248 [TBL] [Abstract][Full Text] [Related]
10. miR-205 Promotes Apoptosis of Cervical Cancer Cells and Enhances Drug Sensitivity of Cisplatin by Inhibiting YAP1. Li X; Li Y; Han Y; Dong B; Liu D; Che L; Liu Y; Wang Y Cancer Biother Radiopharm; 2020 Jun; 35(5):338-344. PubMed ID: 32379984 [No Abstract] [Full Text] [Related]
12. microRNA-382 suppresses the progression of pancreatic cancer through the PI3K/Akt signaling pathway by inhibition of Anxa3. Wan X; Guo D; Zhu Q; Qu R Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G309-G322. PubMed ID: 32463333 [TBL] [Abstract][Full Text] [Related]
13. Microglial Annexin A3 promoted the development of melanoma via activation of hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway. Xu B; Zhang X; Gao Y; Song J; Shi B J Clin Lab Anal; 2021 Feb; 35(2):e23622. PubMed ID: 33118214 [TBL] [Abstract][Full Text] [Related]
14. Annexin A3 is necessary for parallel artery-vein alignment in the mouse retina. Huang K; Crist AM; Patel NR; Blanks A; Carter K; Cleaver O; Meadows SM Dev Dyn; 2020 May; 249(5):666-678. PubMed ID: 32020697 [TBL] [Abstract][Full Text] [Related]
15. Downregulation of annexin A3 promotes ionizing radiation-induced EGFR activation and nuclear translocation and confers radioresistance in nasopharyngeal carcinoma. Yang L; Lu P; Yang X; Li K; Chen X; Zhou Y; Qu S Exp Cell Res; 2022 Sep; 418(2):113292. PubMed ID: 35850266 [TBL] [Abstract][Full Text] [Related]
16. ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin. Jin YF; Huang YT; Chen PF Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3741-3748. PubMed ID: 32329851 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of ANXA3 is an independent prognostic indicator in gastric cancer and its depletion suppresses cell proliferation and tumor growth. Wang K; Li J Oncotarget; 2016 Dec; 7(52):86972-86984. PubMed ID: 27894078 [TBL] [Abstract][Full Text] [Related]
18. The expression of ANXA3 and its relationship with the occurrence and development of breast cancer. Zhou T; Liu S; Yang L; Ju Y; Li C J BUON; 2018; 23(3):713-719. PubMed ID: 30003741 [TBL] [Abstract][Full Text] [Related]
19. MiR‑221 and miR‑222 regulate cell cycle progression and affect chemosensitivity in breast cancer by targeting ANXA3. Kim JY; Jung EJ; Kim JM; Son Y; Lee HS; Kwag SJ; Park JH; Cho JK; Kim HG; Park T; Jeong SH; Jeong CY; Ju YT Exp Ther Med; 2023 Mar; 25(3):127. PubMed ID: 36845963 [TBL] [Abstract][Full Text] [Related]
20. Microglial annexin A3 downregulation alleviates bone cancer-induced pain through inhibiting the Hif-1α/vascular endothelial growth factor signaling pathway. Zhang Z; Deng M; Huang J; Wu J; Li Z; Xing M; Wang J; Guo Q; Zou W Pain; 2020 Dec; 161(12):2750-2762. PubMed ID: 32569086 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]